# TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.

> **NCT02135627** · NA · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 20 (actual)

## Conditions studied

- MALIGNANT GASTROINTESTINAL BLEEDING

## Interventions

- **DRUG:** TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
- **OTHER:** Current standard therapy

## Key facts

- **NCT ID:** NCT02135627
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135627, "TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02135627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*